Back to Search
Start Over
Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
- Source :
- Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p4876-4876, 1p
- Publication Year :
- 2021
-
Abstract
- Objectives:Compared with the general population, patients after allogeneic hematopoietic cell transplantation (HCT) are at higher risk to develop severe disease or die from COVID-19. Immunosuppressive therapy and graft-vs-host disease (GVHD) may abrogate the ability of transplanted patients to mount an adequate immune response to vaccines. We assessed the immune response of patients after allogeneic HCT to the BNT162b2 vaccine (Pfizer-BioNTech) and identified patient and treatment-related factors that predict humoral response in this population.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 138
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs58548393
- Full Text :
- https://doi.org/10.1182/blood-2021-149979